Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784652 | 1.00 | ALDH1A1 (0.34) | ALDH1A1GBA1SMN1; SMN2PRKCAEPHX2 | |
| SCHEMBL2610383 | 0.75 | — | — | |
| SCHEMBL11033685 | 0.75 | ALDH1A1 (0.41) | ALDH1A1GBA1 | |
| SCHEMBL22471680 | 0.74 | ALDH1A1 (0.41) | ALDH1A1GBA1 | |
| Ammonia Solution, Strong SCHEMBL22283017 | 0.73 | ALDH1A1 (0.39) | ALDH1A1GBA1 | |
| SCHEMBL19139101 | 0.70 | — | — | |
| SCHEMBL17351132 | 0.70 | ALDH1A1 (0.41) | ALDH1A1GBA1 | |
| SCHEMBL15009376 | 0.69 | — | — | |
| SCHEMBL17536922 | 0.69 | ALDH1A1 (0.39) | ALDH1A1GBA1SMN1; SMN2 | |
| SCHEMBL5986589 | 0.69 | ALDH1A1 (0.39) | ALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450533-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8450533-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8450533-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-20110124924-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124924-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124924-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2011-05-26 | — | — | US | disclosed |
| WO-2009023980-A1 | CYCLOPROPANATION PROCESS | GIVAUDAN SA (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124924-A1 | Cyclopropanation Process | CBR3, CYP4F3, DBF4 | ALDH1A1 513/4885GBA1 944/4885SMN1; SMN2 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.